Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
- PMID:17433820
- DOI: 10.1016/j.jns.2006.06.030
Therapeutic use of dextromethorphan: key learnings from treatment of pseudobulbar affect
Abstract
A variety of neurological conditions and disease states are accompanied by pseudobulbar affect (PBA), an emotional disorder characterized by uncontrollable outbursts of laughing and crying. The causes of PBA are unclear but may involve lesions in neural circuits regulating the motor output of emotional expression. Several agents used in treating other psychiatric disorders have been applied in the treatment of PBA with some success but data are limited and these agents are associated with unpleasant side effects due to nonspecific activity in diffuse neural networks. Dextromethorphan (DM), a widely used cough suppressant, acts at receptors in the brainstem and cerebellum, brain regions implicated in the regulation of emotional output. The combination of DM and quinidine (Q), an enzyme inhibitor that blocks DM metabolism, has recently been tested in phase III clinical trials in patients with multiple sclerosis and amyotrophic lateral sclerosis and was both safe and effective in palliating PBA symptoms. In addition, clinical studies pertaining to the safety and efficacy of DM/Q in a variety of neurological disease states are ongoing.
Similar articles
- Pseudobulbar affect in multiple sclerosis: toward the development of innovative therapeutic strategies.Miller A.Miller A.J Neurol Sci. 2006 Jun 15;245(1-2):153-9. doi: 10.1016/j.jns.2005.09.018. Epub 2006 May 3.J Neurol Sci. 2006.PMID:16674978Review.
- Dextromethorphan/quinidine for the treatment of pseudobulbar affect.Patatanian E, Casselman J.Patatanian E, et al.Consult Pharm. 2014 Apr;29(4):264-9. doi: 10.4140/TCP.n.2014.264.Consult Pharm. 2014.PMID:24704895Review.
- Effects of dextromethorphan/quinidine on auditory event-related potentials in multiple sclerosis patients with pseudobulbar affect.Haiman G, Pratt H, Miller A.Haiman G, et al.J Clin Psychopharmacol. 2009 Oct;29(5):444-52. doi: 10.1097/JCP.0b013e3181b5ae5c.J Clin Psychopharmacol. 2009.PMID:19745644
- An open-label multicenter study to assess the safety of dextromethorphan/quinidine in patients with pseudobulbar affect associated with a range of underlying neurological conditions.Pattee GL, Wymer JP, Lomen-Hoerth C, Appel SH, Formella AE, Pope LE.Pattee GL, et al.Curr Med Res Opin. 2014 Nov;30(11):2255-65. doi: 10.1185/03007995.2014.940040. Epub 2014 Jul 28.Curr Med Res Opin. 2014.PMID:25062507Free PMC article.Clinical Trial.
- Randomized, controlled trial of dextromethorphan/quinidine for pseudobulbar affect in multiple sclerosis.Panitch HS, Thisted RA, Smith RA, Wynn DR, Wymer JP, Achiron A, Vollmer TL, Mandler RN, Dietrich DW, Fletcher M, Pope LE, Berg JE, Miller A; Psuedobulbar Affect in Multiple Sclerosis Study Group.Panitch HS, et al.Ann Neurol. 2006 May;59(5):780-7. doi: 10.1002/ana.20828.Ann Neurol. 2006.PMID:16634036Clinical Trial.
Cited by
- PKCδ Knockout Mice Are Protected from Dextromethorphan-Induced Serotonergic Behaviors in Mice: Involvements of Downregulation of 5-HT1A Receptor and Upregulation of Nrf2-Dependent GSH Synthesis.Tran HQ, Lee Y, Shin EJ, Jang CG, Jeong JH, Mouri A, Saito K, Nabeshima T, Kim HC.Tran HQ, et al.Mol Neurobiol. 2018 Oct;55(10):7802-7821. doi: 10.1007/s12035-018-0938-7. Epub 2018 Feb 22.Mol Neurobiol. 2018.PMID:29468562
- Persistent pseudobulbar affect secondary to acute disseminated encephalomyelitis.Li Z, Luo S, Ou J, Huang R, Wang Y.Li Z, et al.Socioaffect Neurosci Psychol. 2015 Mar 18;5:26210. doi: 10.3402/snp.v5.26210. eCollection 2015.Socioaffect Neurosci Psychol. 2015.PMID:25792370Free PMC article.
Publication types
MeSH terms
Substances
Related information
LinkOut - more resources
Full Text Sources
Other Literature Sources